Market closed
Nurix Therapeutics/$NRIX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Ticker
$NRIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
284
Website
NRIX Metrics
BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$2.89
EPS
2.22
Beta
-
Dividend rate
Price and volume
Market cap
$1.9B
Beta
2.22
52-week high
$26.86
52-week low
$4.96
Average daily volume
939K
Financial strength
Current ratio
5.285
Quick ratio
5.201
Long term debt to equity
5.464
Total debt to equity
7.202
Management effectiveness
Return on assets (TTM)
-29.46%
Return on equity (TTM)
-57.96%
Valuation
Price to revenue (TTM)
29.548
Price to book
4.85
Price to tangible book (TTM)
4.85
Price to free cash flow (TTM)
-15.597
Growth
Revenue change (TTM)
-17.76%
Earnings per share change (TTM)
5.29%
3-year revenue growth (CAGR)
24.78%
3-year earnings per share growth (CAGR)
6.38%
What the Analysts think about NRIX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
NRIX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NRIX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NRIX News
AllArticlesVideos
Nurix Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
GlobeNewsWire·3 weeks ago
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $1.9B as of November 08, 2024.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of November 08, 2024.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.